BiotechTube

ALXN1920 + Placebo

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Membranous Nephropathy

Conditions

Primary Membranous Nephropathy

Trial Timeline

Sep 19, 2025 → Feb 12, 2027

NCT ID
NCT07157787

About ALXN1920 + Placebo

ALXN1920 + Placebo is a phase 2 stage product being developed by AstraZeneca for Primary Membranous Nephropathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07157787. Target conditions include Primary Membranous Nephropathy.

What happened to similar drugs?

20 of 20 similar drugs in Primary Membranous Nephropathy were approved

Approved (20) Terminated (6) Active (0)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Duloxetine + PlaceboEli LillyApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved
✅RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07157787Phase 2Recruiting

Competing Products

20 competing products in Primary Membranous Nephropathy

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31